Alkermes plc (NASDAQ: ALKS) is 23.44% higher on its value in year-to-date trading and has touched a low of $22.90 and a high of $36.45 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALKS stock was last observed hovering at around $35.84 in the last trading session, with the day’s loss setting it -0.34%.
Currently trading at $35.50, the stock is 8.73% and 15.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing -0.95% at the moment leaves the stock 28.58% off its SMA200. ALKS registered 10.32% gain for a year compared to 6-month gain of 25.75%.
The stock witnessed a 17.94% loss in the last 1 month and extending the period to 3 months gives it a 25.93%, and is 5.97% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.75% over the week and 3.10% over the month.
Alkermes plc (ALKS) has around 1800 employees, a market worth around $5.77B and $1.56B in sales. Current P/E ratio is 16.29 and Fwd P/E is 18.95. Profit margin for the company is 23.57%. Distance from 52-week low is 55.02% and -2.61% from its 52-week high. The company has generated returns on investments over the last 12 months (23.92%).
with sales reaching $312.09M over the same period.The EPS is expected to shrink by -37.12% this year, but quarterly earnings will post -10.40% year-over-year. Quarterly sales are estimated to shrink -10.93% in year-over-year returns.
The shares outstanding are 162.18M, and float is at 158.45M with Short Float at 6.83%.
The top institutional shareholder in the company is BLACKROCK INC. with over 29.11 million shares valued at $701.49 million. The investor’s holdings represent 17.3276 of the ALKS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 20.0 million shares valued at $482.0 million to account for 11.9058 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 14.35 million shares representing 8.5453 and valued at over $345.95 million, while PRICE T ROWE ASSOCIATES INC /MD/ holds 6.5424 of the shares totaling 11.01 million with a market value of $265.4 million.
Alkermes plc (ALKS) Insider Activity
The most recent transaction is an insider sale by Parisi Samuel Joseph, the company’s VP, Finance (Interim PAO). SEC filings show that Parisi Samuel Joseph sold 1,327 shares of the company’s common stock on Feb 20 ’25 at a price of $35.69 per share for a total of $47361.0. Following the sale, the insider now owns 7717.0 shares.
Alkermes plc disclosed in a document filed with the SEC on Feb 12 ’25 that Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold a total of 204,921 shares of the company’s common stock. The trade occurred on Feb 12 ’25 and was made at $32.78 per share for $6.72 million. Following the transaction, the insider now directly holds 57875.0 shares of the ALKS stock.
Still, SEC filings show that on Feb 13 ’25, Hopkinson Craig C. (EVP R&D, Chief Medical Officer) disposed off 144,419 shares at an average price of $35.53 for $5.13 million. The insider now directly holds 57,875 shares of Alkermes plc (ALKS).